# A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine

> **NCT02472548** · PHASE1 · COMPLETED · sponsor: **Dalhousie University** · enrollment: 40 (actual)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** DPX-RSV(A)
- **BIOLOGICAL:** RSV(A)-Alum
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02472548
- **Lead sponsor:** Dalhousie University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2017-03-14
- **Final completion:** 2017-03-14
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02472548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02472548, "A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02472548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*